Our DNA
Born from the Stanford Biodesign methodology—a rigorous framework for identifying unmet clinical needs and inventing scalable solutions.
"De Novo" means "from the beginning." We approach orthopedic challenges without preconceptions, letting clinical evidence guide our innovation.
Identify
Invent
Implement
Impact
Leadership
Chia-Wei Lin, M.D.
Founder
Stanford Biodesign Alumni (2016) • Stanford-Taiwan Biomedical Fellow
Uei-Ming Jow, Ph.D.
Founder
EE Ph.D. Georgia Tech • Former Hardware Engineer at Google
Regulatory Strategy
Sam H. Huang, Ph.D.
Director of Regulatory Affairs, Eko
Stanford-Taiwan Biomedical Fellow
Marketing Strategy
Pei-Lun Li
Sales Manager, Arthrex Taiwan
Software Engineering
Wei-Hsun Huang
Senior Software Engineer, Delta Electronics Inc.
NTHU Ph.D. Candidate
Biomedical Engineering
Heng-Jui Liu
Biomedical Engineer
M.S. BME, NCKU
Medical Advisors
Chih-Hao Chiu, M.D.
Chief, Sports Medicine
CGMH Linkou
En-Rung Chiang, M.D. Ph.D.
Chief, Sports Medicine
Taipei VGH
Innovation Mentors
Guidance from industry pioneers with proven track records in medical device commercialization
Prof. Peter Fitzgerald
Director, Center for Cardiovascular Technology
Stanford Medical School • Co-founder, Triventures
Yue-Teh Jang, Ph.D.
Chairman/CEO, Medeon
Led Kyphon (acq. Medtronic) and Embol-X (acq. Edwards)
Incubation & Recognition
WingHeal was developed through Taiwan's leading biomedical innovation programs
NCKU SPARK Program
Translational research program modeled after Stanford SPARK, focused on de-risking early-stage biomedical innovations
MOST Seedling Program (育苗計畫)
National Science and Technology Council program supporting commercialization of academic research
These programs provided mentorship, clinical validation support, and IP strategy guidance that shaped WingHeal from concept to pre-clinical prototype.
Interested in Collaboration?
Clinical partnerships • Research collaboration • Investment opportunities
Contact Us